Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase (DISRUPT)

Brief description of study

The purpose of this superiority study is to evaluate the efficacy and safety of exebacase in addition to standard of care antibiotics (SoCA) compared with SoCA alone for the treatment of patients with Staphylococcus aureus (S. aureus) bloodstream infections (BSI), including right-sided infective endocarditis (IE). Patients will be randomized to receive a single intravenous dose of exebacase or placebo. Patients will receive SoCA selected by the investigators based on the protocol.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
S. aureus bloodstream infection,S. aureus bacteremia,S. aureus right-sided infective endocarditis
Age: Between 12 Years - 99 Years
Gender: All

Male or female, 12 years or older, Blood culture positive for S. aureus, two signs or symptoms attributable to S. aureus BSI/IE

Updated on 09 Mar 2024. Study ID: 843298

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).